You are here

Article info

Article menu

Download PDFPDF

Review
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets

Authors

  • Vladimir Laletin Immunity and Cancer, Cancer Research Centre Marseille, Marseille, FranceOnco-hematology and immuno-oncology (OHIO), Centre de Recherche en Cancérologie de Marseille, Marseille, France PubMed articlesGoogle scholar articles
  • Pierre-Louis Bernard Immunity and Cancer, Cancer Research Centre Marseille, Marseille, FranceOnco-hematology and immuno-oncology (OHIO), Centre de Recherche en Cancérologie de Marseille, Marseille, France PubMed articlesGoogle scholar articles
  • Cathy Costa da Silva Immunity and Cancer, Cancer Research Centre Marseille, Marseille, FranceOnco-hematology and immuno-oncology (OHIO), Centre de Recherche en Cancérologie de Marseille, Marseille, France PubMed articlesGoogle scholar articles
  • Geoffrey Guittard Immunity and Cancer, Cancer Research Centre Marseille, Marseille, FranceOnco-hematology and immuno-oncology (OHIO), Centre de Recherche en Cancérologie de Marseille, Marseille, France PubMed articlesGoogle scholar articles
  • Jacques A Nunes Immunity and Cancer, Cancer Research Centre Marseille, Marseille, FranceOnco-hematology and immuno-oncology (OHIO), Centre de Recherche en Cancérologie de Marseille, Marseille, France PubMed articlesGoogle scholar articles

Citation

Laletin V, Bernard P, Costa da Silva C, et al
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets
Journal for ImmunoTherapy of Cancer 2023;11:e005845. doi: 10.1136/jitc-2022-005845
Online issue publication 
May 22, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.